The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
The firm believes the IsoPSA technology is superior to competitors, but clinicians argue that a lack of comparative studies could hamper adoption of all these tests.
The test uses the company's SIA platform, a protein biomarker technology that measures different protein isoform populations to assess patient disease states.
